Abstract
Cancer-homing toxins are a group of man-made cytotoxic molecules targeting cancer cells. In the past decade they have demonstrated potential as cancer therapeutics. These molecules contain a toxin, natural or usually derivatized, connected to a cancerhoming module, such as a monoclonal antibody or growth factor or their derivatives. Various cancer-homing toxins have been designed and tested in cell-lines, animalmodels and clinical trials. We review some of these data and discuss ways to better design cancer-homing toxins in the light of advances in cancer genomics, antibodyengineering techniques and computational algorithms.
Keywords: Downregulation, Toxins, Targeted-therapy, Cancer, Vascular-leak syndrome, Drug- design, Super-antigen, Clinicaltrials
Current Pharmaceutical Design
Title: Cancer-Homing Toxins
Volume: 8 Issue: 22
Author(s): H. C. Ng and H. E. Khoo
Affiliation:
Keywords: Downregulation, Toxins, Targeted-therapy, Cancer, Vascular-leak syndrome, Drug- design, Super-antigen, Clinicaltrials
Abstract: Cancer-homing toxins are a group of man-made cytotoxic molecules targeting cancer cells. In the past decade they have demonstrated potential as cancer therapeutics. These molecules contain a toxin, natural or usually derivatized, connected to a cancerhoming module, such as a monoclonal antibody or growth factor or their derivatives. Various cancer-homing toxins have been designed and tested in cell-lines, animalmodels and clinical trials. We review some of these data and discuss ways to better design cancer-homing toxins in the light of advances in cancer genomics, antibodyengineering techniques and computational algorithms.
Export Options
About this article
Cite this article as:
Ng C. H. and Khoo E. H., Cancer-Homing Toxins, Current Pharmaceutical Design 2002; 8 (22) . https://dx.doi.org/10.2174/1381612023393477
DOI https://dx.doi.org/10.2174/1381612023393477 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors
Current Topics in Medicinal Chemistry Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Dependence of DPPH Radical Scavenging Activity of Dietary Flavonoid Quercetin on Reaction Environment
Mini-Reviews in Medicinal Chemistry Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?
Current Cancer Drug Targets Glyco-Nanomaterials: Translating Insights from the “Sugar-Code” to Biomedical Applications
Current Medicinal Chemistry Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Current Medicinal Chemistry Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Imaging of Hypoxia Using PET and MRI
Current Pharmaceutical Biotechnology Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up
Current Pharmaceutical Design Omega-3 Fatty Acid Treatment Combined with Chemotherapy to Prevent Toxicity, Drug Resistance, and Metastasis in Cancer
Current Drug Targets N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Target Therapies in Pancreatic Carcinoma
Current Medicinal Chemistry